Yumanity Therapeutics (YMTX) Competitors

$0.63
+0.11 (+20.96%)
(As of 04/22/2024 ET)

YMTX vs. LUMO, ONTX, VINC, SYBX, MEIP, HUGE, BIVI, FLGC, RNXT, and CPIX

Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Lumos Pharma (LUMO), Onconova Therapeutics (ONTX), Vincerx Pharma (VINC), Synlogic (SYBX), MEI Pharma (MEIP), FSD Pharma (HUGE), BioVie (BIVI), Flora Growth (FLGC), RenovoRx (RNXT), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.

Yumanity Therapeutics vs.

Yumanity Therapeutics (NASDAQ:YMTX) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.

In the previous week, Lumos Pharma had 1 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 2 mentions for Lumos Pharma and 1 mentions for Yumanity Therapeutics. Yumanity Therapeutics' average media sentiment score of 0.00 equaled Lumos Pharma'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Yumanity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lumos Pharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lumos Pharma has a consensus target price of $18.00, suggesting a potential upside of 520.69%. Given Lumos Pharma's higher probable upside, analysts plainly believe Lumos Pharma is more favorable than Yumanity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yumanity Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Lumos Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

25.1% of Yumanity Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are owned by institutional investors. 12.5% of Yumanity Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lumos Pharma has lower revenue, but higher earnings than Yumanity Therapeutics. Lumos Pharma is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yumanity Therapeutics$4.84M1.42-$39.50M-$3.00-0.21
Lumos Pharma$2.05M11.49-$34.03M-$4.19-0.69

Lumos Pharma received 20 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. Likewise, 77.27% of users gave Lumos Pharma an outperform vote while only 70.00% of users gave Yumanity Therapeutics an outperform vote.

CompanyUnderperformOutperform
Yumanity TherapeuticsOutperform Votes
14
70.00%
Underperform Votes
6
30.00%
Lumos PharmaOutperform Votes
34
77.27%
Underperform Votes
10
22.73%

Yumanity Therapeutics has a net margin of -660.61% compared to Lumos Pharma's net margin of -1,659.39%. Lumos Pharma's return on equity of -85.63% beat Yumanity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Yumanity Therapeutics-660.61% -263.34% -107.08%
Lumos Pharma -1,659.39%-85.63%-65.30%

Yumanity Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Summary

Lumos Pharma beats Yumanity Therapeutics on 12 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YMTX vs. The Competition

MetricYumanity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.89M$6.44B$4.83B$7.54B
Dividend YieldN/A3.07%5.47%3.96%
P/E Ratio-0.217.08173.7515.92
Price / Sales1.42304.502,459.3782.01
Price / CashN/A29.1345.6834.56
Price / Book0.285.614.664.31
Net Income-$39.50M$139.22M$102.38M$213.66M
7 Day Performance35.09%-0.19%0.41%1.53%
1 Month Performance-2.31%-8.48%-5.79%-3.91%
1 Year Performance-84.21%1.53%9.99%8.20%

Yumanity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LUMO
Lumos Pharma
1.5177 of 5 stars
$2.52
+2.9%
$18.00
+614.3%
-12.6%$20.44M$2.05M-0.6033Upcoming Earnings
Gap Up
ONTX
Onconova Therapeutics
0.9924 of 5 stars
N/A$11.00
+∞
-8.7%$20.90M$230,000.00-1.0916Analyst Report
News Coverage
High Trading Volume
VINC
Vincerx Pharma
2.3006 of 5 stars
$0.94
+8.0%
$5.00
+432.1%
0.0%$20.12MN/A-0.5041
SYBX
Synlogic
1.8067 of 5 stars
$1.80
flat
$65.00
+3,511.1%
-80.4%$20.97M$3.37M-0.176Gap Down
MEIP
MEI Pharma
4.0917 of 5 stars
$3.19
-1.8%
$7.00
+119.8%
-30.7%$21.21M$48.82M1.0746Analyst Report
HUGE
FSD Pharma
0 of 5 stars
$0.50
-3.8%
N/A-70.6%$19.68MN/A-1.0617News Coverage
Gap Down
BIVI
BioVie
1.4009 of 5 stars
$0.49
flat
$8.00
+1,539.3%
-93.7%$19.48MN/A-0.4218Positive News
Gap Up
FLGC
Flora Growth
2.5471 of 5 stars
$1.82
+0.6%
$7.00
+284.6%
-60.5%$19.46M$76.07M-0.18337Gap Down
RNXT
RenovoRx
0.6242 of 5 stars
$1.14
-0.9%
$8.50
+645.6%
-59.9%$19.23MN/A-1.1310
CPIX
Cumberland Pharmaceuticals
0 of 5 stars
$1.56
+0.6%
N/A-14.6%$22.12M$39.55M-3.5591Analyst Report
Gap Down

Related Companies and Tools

This page (NASDAQ:YMTX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners